4 results on '"Haina Abel"'
Search Results
2. Electrocardiographic Safety of Repeated Monthly Dihydroartemisinin-Piperaquine as a Candidate for Mass Drug Administration
- Author
-
Harin Karunajeewa, Oriol Mitjà, Laurens Manning, Rhoda Ila, Kevin Pulai, Quique Bassat, Sergi Sanz, Brioni R. Moore, Pere Millat-Martinez, Moses Laman, Leanne J. Robinson, and Haina Abel
- Subjects
0301 basic medicine ,Adult ,Male ,medicine.medical_specialty ,Adolescent ,030106 microbiology ,Malària ,Clinical Therapeutics ,QT interval ,Drug Administration Schedule ,03 medical and health sciences ,Antimalarials ,Papua New Guinea ,Electrocardiography ,Dihydroartemisinin/piperaquine ,Electrocardiografia ,Internal medicine ,medicine ,Malaria, Vivax ,Humans ,Pharmacology (medical) ,Prospective Studies ,Time point ,Malaria, Falciparum ,Child ,Pharmacology ,Cardiotoxicity ,medicine.diagnostic_test ,business.industry ,Absolute risk reduction ,QTcF Prolongation ,Middle Aged ,Confidence interval ,Artemisinins ,Healthy Volunteers ,Malaria ,Drug Combinations ,Long QT Syndrome ,Infectious Diseases ,Child, Preschool ,Quinolines ,Mass Drug Administration ,Female ,Patient Safety ,business - Abstract
Mass drug administration (MDA) of sequential rounds of antimalarial drugs is being considered for use as a tool for malaria elimination. As an effective and long-acting antimalarial, dihydroartemisinin-piperaquine (DHA-PQP) appears to be suitable as a candidate for MDA. However, the absence of cardiac safety data following repeated administration hinders its use in the extended schedules proposed for MDA. We conducted an interventional study in Lihir Island, Papua New Guinea, using healthy individuals age 3 to 60 years who received a standard 3-day course of DHA-PQP on 3 consecutive months. Twelve-lead electrocardiography (ECG) readings were conducted predose and 4 h after the final dose of each month. The primary safety endpoint was QT interval correction (QTc using Fridericia’s correction [QTcF]) prolongation from baseline to 4 h postdosing. We compared the difference in prolongations between the third course postdose and the first course postdose. Of 84 enrolled participants, 69 (82%) participants completed all treatment courses and ECG measurements. The average increase in QTcF was 19.6 ms (standard deviation [SD], 17.8 ms) and 17.1 ms (SD, 17.1 ms) for the first-course and third-course postdosing ECGs risk difference, −2.4 (95% confidence interval [95% CI], −6.9 to 2.1; P = 0.285), respectively. We recorded a QTcF prolongation of >60 ms from baseline in 3 (4.3%) and 2 (2.9%) participants after the first course and third course (P = 1.00), respectively. No participants had QTcF intervals of >500 ms at any time point. Three consecutive monthly courses of DHA-PQP were as safe as a single course. The absence of cumulative cardiotoxicity with repeated dosing supports the use of monthly DHA-PQP as part of malaria elimination strategies.
- Published
- 2018
3. Re-emergence of yaws after single mass azithromycin treatment followed by targeted treatment: a longitudinal study
- Author
-
Wendy Houinei, Camila González-Beiras, Alyssa E. Barry, Charmie Godornes, James Wangi, August Kapa, Sergi Sanz, Sheila A. Lukehart, Oriol Mitjà, Sibauk Bieb, Raymond Paru, Haina Abel, and Quique Bassat
- Subjects
Male ,Pediatrics ,Longitudinal study ,genetic structures ,Prevalence ,Azithromycin ,Úlceres ,Communicable Diseases, Emerging ,Polymerase Chain Reaction ,Serology ,0302 clinical medicine ,Epidemiology ,030212 general & internal medicine ,Longitudinal Studies ,Child ,Children ,Ulcers ,education.field_of_study ,Treponema ,biology ,General Medicine ,3. Good health ,Anti-Bacterial Agents ,RNA, Ribosomal, 23S ,Treatment Outcome ,Child, Preschool ,Mass Drug Administration ,Female ,Macrolides ,Infants ,medicine.drug ,medicine.medical_specialty ,Adolescent ,030231 tropical medicine ,Population ,Article ,03 medical and health sciences ,Papua New Guinea ,Drug Resistance, Bacterial ,medicine ,Humans ,Treponema pallidum ,Disease Eradication ,education ,business.industry ,Genetic Variation ,Infant ,Single mass ,biology.organism_classification ,Yaws ,business - Abstract
Yaws is a substantial cause of chronic disfiguring ulcers in children in at least 14 countries in the tropics. WHO's newly adopted strategy for yaws eradication uses a single round of mass azithromycin treatment followed by targeted treatment programmes, and data from pilot studies have shown a short-term significant reduction of yaws. We assessed the long-term efficacy of the WHO strategy for yaws eradication.Between April 15, 2013, and Oct 24, 2016, we did a longitudinal study on a Papua New Guinea island (Lihir; 16 092 population) in which yaws was endemic. In the initial study, the participants were followed for 12 months; in this extended follow-up study, clinical, serological, and PCR surveys were continued every 6 months for 42 months. We used genotyping and travel history to identify importation events. Active yaws confirmed by PCR specific for Treponema pallidum was the primary outcome indicator. The study is registered with ClinicalTrials.gov, number NCT01955252.Mass azithromycin treatment (coverage rate of 84%) followed by targeted treatment programmes reduced the prevalence of active yaws from 1·8% to a minimum of 0·1% at 18 months (difference from baseline -1·7%, 95% CI, -1·9 to -1·4; p0·0001), but the infection began to re-emerge after 24 months with a significant increase to 0·4% at 42 months (difference from 18 months 0·3%, 95% CI 0·1 to 0·4; p0·0001). At each timepoint after baseline, more than 70% of the total community burden of yaws was found in individuals who had not had the mass treatment or as new infections in non-travelling residents. At months 36 and 42, five cases of active yaws, all from the same village, showed clinical failure following azithromycin treatment, with PCR-detected mutations in the 23S ribosomal RNA genes conferring resistance to azithromycin. A sustained decrease in the prevalence of high-titre latent yaws from 13·7% to1·5% in asymptomatic children aged 1-5 years old and of genetic diversity of yaws strains from 0·139 to less than 0·046 between months 24 and 42 indicated a reduction in transmission of infection.The implementation of the WHO strategy did not, in the long-term, achieve elimination in a high-endemic community mainly due to the individuals who were absent at the time of mass treatment in whom yaws reactivated; repeated mass treatment might be necessary to eliminate yaws. To our knowledge, this is the first report of the emergence of azithromycin-resistant T p pertenue and spread within one village. Communities' surveillance should be strengthened to detect any possible treatment failure and biological markers of resistance.ISDIN laboratories, Newcrest Mining Limited, and US Public Health Service National Institutes of Health.
- Published
- 2017
4. Effectiveness of single-dose azithromycin to treat latent yaws: a longitudinal comparative cohort study
- Author
-
Sibauk Bieb, Reman Kolmau, August Kapa, Wendy Houinei, Oriol Mitjà, Charmie Godornes, Camila González-Beiras, James Wangi, Sergi Sanz, Sheila A. Lukehart, Raymond Paru, Quique Bassat, Haina Abel, and Kingsley Asiedu
- Subjects
Male ,medicine.medical_specialty ,Adolescent ,genetic structures ,030231 tropical medicine ,Population ,Azithromycin ,Polymerase Chain Reaction ,Rapid plasma reagin ,Serology ,Cohort Studies ,Papua New Guinea ,03 medical and health sciences ,0302 clinical medicine ,Clinical trials ,Radiation victims ,Internal medicine ,medicine ,Clinical endpoint ,Humans ,Longitudinal Studies ,Treponema pallidum ,030212 general & internal medicine ,Child ,education ,skin and connective tissue diseases ,education.field_of_study ,medicine.diagnostic_test ,Transmission (medicine) ,business.industry ,lcsh:Public aspects of medicine ,Absolute risk reduction ,lcsh:RA1-1270 ,General Medicine ,Anti-Bacterial Agents ,Surgery ,body regions ,Víctimes de radiacions ,Child, Preschool ,Yaws ,Female ,business ,medicine.drug ,Cohort study ,Assaigs clínics - Abstract
BACKGROUND: Treatment of latent yaws is a crucial component of the WHO yaws eradication strategy to prevent relapse and the resulting transmission to uninfected children. We assessed the effectiveness of single-dose azithromycin to treat patients with latent yaws. METHODS: This population-based cohort study included children (age /=1:8) latent or active yaws, between April, 2013, and May, 2015. Latent yaws was defined as lack of suspicious skin lesions or presence of ulcers negative for Treponema pallidum subsp pertenue on PCR, and active yaws was defined as ulcers positive for T pertenue on PCR. All children received one oral dose of 30 mg/kg azithromycin. The primary endpoint was serological cure, defined as a two-dilution decrease in rapid plasma reagin titre by 24 months after treatment. Treatment of latent yaws was taken to be non-inferior to that of active yaws if the lower limit of the two-sided 95% CI for the difference in rates was higher than or equal to -10%. This study is registered with ClinicalTrials.gov, number NCT01955252. FINDINGS: Of 311 participants enrolled, 273 (88%; 165 with latent yaws and 108 with active yaws) completed follow-up. The primary endpoint was achieved in 151 (92%) participants with latent yaws and 101 (94%) with active yaws (risk difference -2.0%, 95% CI -8.3 to 4.3), meeting the prespecified criteria for non-inferiority. INTERPRETATION: On the basis of decline in serological titre, oral single-dose azithromycin was effective in participants with latent yaws. This finding supports the WHO strategy for the eradication of yaws based on mass administration of the entire endemic community irrespective of clinical status. FUNDING: Newcrest Mining Limited and ISDIN laboratories.
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.